FDA Approves Brexanolone (Zulresso), First Drug for Postpartum Depression FDA Approves Brexanolone (Zulresso), First Drug for Postpartum Depression

The drug can be given only in a certified facility, and women will have to stay for the entire 2.5 days it takes for the infusion.FDA Approvals
Source: Medscape Psychiatry Headlines - Category: Psychiatry Tags: Ob/Gyn & Women ' s Health News Alert Source Type: news